South Africa is a highly desirable location for the HIV-vaccine research. The DST argues that the South African HIV/Aids Research (and Innovation) Platform, Sharp, was launched in July 2009 as a means of "revisiting" its expectations of the HIV-vaccine research in favour of a "strategic combination of interventions", whatever that means. This is not acceptable. Sharp currently supports nine research projects but none of them compares to that of SAAVI.